세계의 고지혈증 시장 보고서(2025년)

Hyperlipidemia is a medical condition marked by elevated levels of lipids (fats) in the bloodstream, including cholesterol and triglycerides. This metabolic disorder is common and represents a substantial risk factor for cardiovascular diseases.

Hyperlipidemia can be classified into two main types such as familial and acquired. Familial hyperlipidemia is a genetic disorder characterized by hereditary high lipid levels, notably cholesterol and triglycerides, significantly increasing the risk of cardiovascular diseases. Treatment options encompass medications like statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and others. These medications can be administered orally or through injection. They serve various end-users, including hospitals, specialty clinics, home care services, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hyperlipidemia market research report is one of a series of new reports from The Business Research Company that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperlipidemia market size has grown steadily in recent years. It will grow from $20.24 billion in 2024 to $20.92 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $24.24 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

The forecast of 3.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. healthcare by driving up the cost of novel RNA-based lipid-lowering therapies and lipoprotein apheresis machines imported from Belgium and Israel, exacerbating preventive cardiology program expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of chronic disorders, particularly heart disease, is expected to drive the growth of the hyperlipidemia market in the future. Heart diseases encompass various conditions that impact the heart and its functioning. Treatment for hyperlipidemia assists individuals with heart disease by reducing the risk of heart attacks, preventing strokes, improving endothelial function, and decreasing the necessity for invasive procedures. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females living with these conditions. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths each year, or roughly 480 deaths per day, which translates to one death every three minutes. Consequently, the increasing prevalence of chronic disorders such as heart disease is driving the expansion of the hyperlipidemia market.

The increasing prevalence of smoking is expected to drive the growth of the hyperlipidemia market in the future. Smoking involves the consumption of tobacco through combustion, leading to the inhalation of smoke and the absorption of various components into the bloodstream. Smoking is closely linked to risk factors associated with hyperlipidemia, such as obesity and insulin resistance. These risk factors can contribute to dyslipidemia, characterized by abnormal lipid levels, which can eventually lead to the development of hyperlipidemia. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking is a driving factor in the hyperlipidemia market.

Key players in the hyperlipidemia market are concentrating on developing innovative products, including advanced therapies for lowering low-density lipoprotein cholesterol, to maintain their market position. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced the approval of Praluent (alirocumab) Injection by the U.S. Food & Drug Administration (FDA). This represents a significant advancement in the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted method to manage dangerously high low-density lipoprotein cholesterol (LDL-C) levels. The recent FDA approval is backed by Phase 3 trial results, which demonstrated a 31% reduction in LDL-C levels with regular dosing. Its well-established safety profile, consistent with that observed in adults, offers reassurance to families and healthcare providers. Additionally, as the first therapy targeting the genetically-validated PCSK9 protein, Praluent marks a milestone in heart disease treatment. Together, these attributes position Praluent as an essential option for managing high cholesterol in children with HeFH.

In March 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology firm, finalized the acquisition of Arena Pharmaceuticals for an undisclosed sum. This strategic move by Pfizer is driven by the company's goal of broadening its product portfolio through the addition of Arena Pharmaceuticals' ongoing clinical-stage projects, which hold promise for the advancement of innovative therapies targeting various immuno-inflammatory diseases. Arena Pharmaceuticals, situated in the United States, is recognized for its specialization in biopharmaceuticals and the development of medications, including those designed to address high cholesterol and hyperlipidemia.

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hyperlipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperlipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hyperlipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hyperlipidemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Familial; Acquired
• 2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
• 3) By Route of Administration: Oral; Parenteral
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH); Familial Combined Hyperlipidemia; Familial Dysbetalipoproteinemia
• 2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia; Secondary Hyperlipidemia; Drug-Induced Hyperlipidemia
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi-Aventis LLC.; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Eli Lilly and Co Ltd.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Limited; Otsuka Pharmaceutical Co. Ltd.; Menarini Group; Ipsen S.A.; Dr. Reddy's Laboratories Ltd.; Apotex Inc.; Hikma Pharmaceuticals PLC; Cipla Inc.; Endo International plc; Aspen Pharmacare Holdings Limited; Zydus Lifesciences Ltd.; LEO Pharma A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hyperlipidemia Market Characteristics

3. Hyperlipidemia Market Trends And Strategies

4. Hyperlipidemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hyperlipidemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hyperlipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hyperlipidemia Market Growth Rate Analysis
• 5.4. Global Hyperlipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hyperlipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hyperlipidemia Total Addressable Market (TAM)

6. Hyperlipidemia Market Segmentation

• 6.1. Global Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial
• Acquired
• 6.2. Global Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Combination
• Other Treatment
• 6.3. Global Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Hyperlipidemia Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.5. Global Hyperlipidemia Market, Sub-Segmentation Of Familial Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial Hypercholesterolemia (FH)
• Familial Combined Hyperlipidemia
• Familial Dysbetalipoproteinemia
• 6.6. Global Hyperlipidemia Market, Sub-Segmentation Of Acquired Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diet-Related Hyperlipidemia
• Secondary Hyperlipidemia
• Drug-Induced Hyperlipidemia

7. Hyperlipidemia Market Regional And Country Analysis

• 7.1. Global Hyperlipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hyperlipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hyperlipidemia Market

• 8.1. Asia-Pacific Hyperlipidemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hyperlipidemia Market

• 9.1. China Hyperlipidemia Market Overview
• 9.2. China Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hyperlipidemia Market

• 10.1. India Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hyperlipidemia Market

• 11.1. Japan Hyperlipidemia Market Overview
• 11.2. Japan Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hyperlipidemia Market

• 12.1. Australia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hyperlipidemia Market

• 13.1. Indonesia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hyperlipidemia Market

• 14.1. South Korea Hyperlipidemia Market Overview
• 14.2. South Korea Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hyperlipidemia Market

• 15.1. Western Europe Hyperlipidemia Market Overview
• 15.2. Western Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hyperlipidemia Market

• 16.1. UK Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hyperlipidemia Market

• 17.1. Germany Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hyperlipidemia Market

• 18.1. France Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hyperlipidemia Market

• 19.1. Italy Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hyperlipidemia Market

• 20.1. Spain Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hyperlipidemia Market

• 21.1. Eastern Europe Hyperlipidemia Market Overview
• 21.2. Eastern Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hyperlipidemia Market

• 22.1. Russia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hyperlipidemia Market

• 23.1. North America Hyperlipidemia Market Overview
• 23.2. North America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hyperlipidemia Market

• 24.1. USA Hyperlipidemia Market Overview
• 24.2. USA Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hyperlipidemia Market

• 25.1. Canada Hyperlipidemia Market Overview
• 25.2. Canada Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hyperlipidemia Market

• 26.1. South America Hyperlipidemia Market Overview
• 26.2. South America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hyperlipidemia Market

• 27.1. Brazil Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hyperlipidemia Market

• 28.1. Middle East Hyperlipidemia Market Overview
• 28.2. Middle East Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hyperlipidemia Market

• 29.1. Africa Hyperlipidemia Market Overview
• 29.2. Africa Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hyperlipidemia Market Competitive Landscape And Company Profiles

• 30.1. Hyperlipidemia Market Competitive Landscape
• 30.2. Hyperlipidemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Hyperlipidemia Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi-Aventis LLC.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc.
• 31.5. Eli Lilly and Co Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sun Pharmaceutical Industries Limited
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Menarini Group
• 31.12. Ipsen S.A.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Apotex Inc.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Hyperlipidemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hyperlipidemia Market

34. Recent Developments In The Hyperlipidemia Market

35. Hyperlipidemia Market High Potential Countries, Segments and Strategies

• 35.1 Hyperlipidemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hyperlipidemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hyperlipidemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer